Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2

Masako Tanaka, Maki Yamaguchi, Masayuki Shiota, Yukiko Kawamoto, Katsuyuki Takahashi, Azusa Inagaki, Mayuko Osada-Oka, Akihito Harada, Hideki Wanibuchi, Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao, Yasuyuki Ohkawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fibroblast growth factor-2 (FGF-2) plays a critical role in endothelial survival, proliferation, and angiogenesis and is localized on the cell membrane by binding to heparan sulfate proteoglycans. Here we established a neutralizing monoclonal antibody, 1B9B9, against FGF-2 using the rat medial iliac lymph node method. 1B9B9 blocked the binding of FGF-2 to its receptor, inhibiting FGF-2-induced proliferation and corresponding downstream signaling in endothelial cells. Treatment of human umbilical vein endothelial cells with 1B9B9 reduced the basal phosphorylation levels of Akt and MAPK. Furthermore, continued treatment with 1B9B9 induced cell death by apoptosis. Compared with FGF-2 knockdown, 1B9B9 significantly reduced cell survival. In addition, the combination of FGF-2 siRNA and 1B9B9 showed a synergistic effect. The data indicate that 1B9B9 established by the rat iliac lymph node method is a fully compatible neutralizing antibody.

Original languageEnglish
Pages (from-to)261-269
Number of pages9
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Volume33
Issue number4
DOIs
Publication statusPublished - 2014 Aug 1
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 2
Monoclonal Antibodies
Neutralizing Antibodies
Lymph Nodes
Receptor, Fibroblast Growth Factor, Type 2
Heparan Sulfate Proteoglycans
Human Umbilical Vein Endothelial Cells
Small Interfering RNA
Cell Survival
Cell Death
Endothelial Cells
Phosphorylation
Cell Membrane
Apoptosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2. / Tanaka, Masako; Yamaguchi, Maki; Shiota, Masayuki; Kawamoto, Yukiko; Takahashi, Katsuyuki; Inagaki, Azusa; Osada-Oka, Mayuko; Harada, Akihito; Wanibuchi, Hideki; Izumi, Yasukatsu; Miura, Katsuyuki; Iwao, Hiroshi; Ohkawa, Yasuyuki.

In: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol. 33, No. 4, 01.08.2014, p. 261-269.

Research output: Contribution to journalArticle

Tanaka, M, Yamaguchi, M, Shiota, M, Kawamoto, Y, Takahashi, K, Inagaki, A, Osada-Oka, M, Harada, A, Wanibuchi, H, Izumi, Y, Miura, K, Iwao, H & Ohkawa, Y 2014, 'Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2', Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, vol. 33, no. 4, pp. 261-269. https://doi.org/10.1089/mab.2013.0085
Tanaka, Masako ; Yamaguchi, Maki ; Shiota, Masayuki ; Kawamoto, Yukiko ; Takahashi, Katsuyuki ; Inagaki, Azusa ; Osada-Oka, Mayuko ; Harada, Akihito ; Wanibuchi, Hideki ; Izumi, Yasukatsu ; Miura, Katsuyuki ; Iwao, Hiroshi ; Ohkawa, Yasuyuki. / Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2. In: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2014 ; Vol. 33, No. 4. pp. 261-269.
@article{58630aeff19a494e9b08e3e5b84996b5,
title = "Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2",
abstract = "Fibroblast growth factor-2 (FGF-2) plays a critical role in endothelial survival, proliferation, and angiogenesis and is localized on the cell membrane by binding to heparan sulfate proteoglycans. Here we established a neutralizing monoclonal antibody, 1B9B9, against FGF-2 using the rat medial iliac lymph node method. 1B9B9 blocked the binding of FGF-2 to its receptor, inhibiting FGF-2-induced proliferation and corresponding downstream signaling in endothelial cells. Treatment of human umbilical vein endothelial cells with 1B9B9 reduced the basal phosphorylation levels of Akt and MAPK. Furthermore, continued treatment with 1B9B9 induced cell death by apoptosis. Compared with FGF-2 knockdown, 1B9B9 significantly reduced cell survival. In addition, the combination of FGF-2 siRNA and 1B9B9 showed a synergistic effect. The data indicate that 1B9B9 established by the rat iliac lymph node method is a fully compatible neutralizing antibody.",
author = "Masako Tanaka and Maki Yamaguchi and Masayuki Shiota and Yukiko Kawamoto and Katsuyuki Takahashi and Azusa Inagaki and Mayuko Osada-Oka and Akihito Harada and Hideki Wanibuchi and Yasukatsu Izumi and Katsuyuki Miura and Hiroshi Iwao and Yasuyuki Ohkawa",
year = "2014",
month = "8",
day = "1",
doi = "10.1089/mab.2013.0085",
language = "English",
volume = "33",
pages = "261--269",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2

AU - Tanaka, Masako

AU - Yamaguchi, Maki

AU - Shiota, Masayuki

AU - Kawamoto, Yukiko

AU - Takahashi, Katsuyuki

AU - Inagaki, Azusa

AU - Osada-Oka, Mayuko

AU - Harada, Akihito

AU - Wanibuchi, Hideki

AU - Izumi, Yasukatsu

AU - Miura, Katsuyuki

AU - Iwao, Hiroshi

AU - Ohkawa, Yasuyuki

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Fibroblast growth factor-2 (FGF-2) plays a critical role in endothelial survival, proliferation, and angiogenesis and is localized on the cell membrane by binding to heparan sulfate proteoglycans. Here we established a neutralizing monoclonal antibody, 1B9B9, against FGF-2 using the rat medial iliac lymph node method. 1B9B9 blocked the binding of FGF-2 to its receptor, inhibiting FGF-2-induced proliferation and corresponding downstream signaling in endothelial cells. Treatment of human umbilical vein endothelial cells with 1B9B9 reduced the basal phosphorylation levels of Akt and MAPK. Furthermore, continued treatment with 1B9B9 induced cell death by apoptosis. Compared with FGF-2 knockdown, 1B9B9 significantly reduced cell survival. In addition, the combination of FGF-2 siRNA and 1B9B9 showed a synergistic effect. The data indicate that 1B9B9 established by the rat iliac lymph node method is a fully compatible neutralizing antibody.

AB - Fibroblast growth factor-2 (FGF-2) plays a critical role in endothelial survival, proliferation, and angiogenesis and is localized on the cell membrane by binding to heparan sulfate proteoglycans. Here we established a neutralizing monoclonal antibody, 1B9B9, against FGF-2 using the rat medial iliac lymph node method. 1B9B9 blocked the binding of FGF-2 to its receptor, inhibiting FGF-2-induced proliferation and corresponding downstream signaling in endothelial cells. Treatment of human umbilical vein endothelial cells with 1B9B9 reduced the basal phosphorylation levels of Akt and MAPK. Furthermore, continued treatment with 1B9B9 induced cell death by apoptosis. Compared with FGF-2 knockdown, 1B9B9 significantly reduced cell survival. In addition, the combination of FGF-2 siRNA and 1B9B9 showed a synergistic effect. The data indicate that 1B9B9 established by the rat iliac lymph node method is a fully compatible neutralizing antibody.

UR - http://www.scopus.com/inward/record.url?scp=84907033952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907033952&partnerID=8YFLogxK

U2 - 10.1089/mab.2013.0085

DO - 10.1089/mab.2013.0085

M3 - Article

C2 - 25171006

AN - SCOPUS:84907033952

VL - 33

SP - 261

EP - 269

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 4

ER -